FLU vaccine efficacyInfluenza viruses are constantly evolving and are therefore monitored worldwide in the hope to reduce the burden of disease by annual updates to vaccine recommendations. We conducted genomic sequencing of 110 influenza A and 30 influenza B viruses from specimens collected between ...
The global influenza vaccine market size was valued at USD 7.97 billion in 2023 and is projected to grow from USD 8.55 billion in 2024 to USD 17.77 billion by 2032, exhibiting a CAGR of 9.6% during the forecast (2024-2032). North America accounted for a market value of USD 4.28 billion ...
The global influenza vaccine market size was valued at USD 7.91 billion in 2023 and is expected to grow at a CAGR of 6.98% from 2024 to 2030
There is an unmet need for new influenza vaccine strategies that compensate for impaired vaccine responses in elderly individuals. Here, we evaluated the effectiveness of a single-stranded RNA (ssRNA) as an adjuvant to enhance the efficacy of inactivated influenza vaccine (IIV) in mouse models. Im...
the seasonal influenza vaccine composition is updated every year by the circulating strains to enhance protection.According to the World Health Organization, when the vaccine strains closely match the circulating influenza viruses, the efficacy of inactivated influenza vaccine (IIV) in individuals younger ...
Influenza is a vaccine-preventable disease. • Currently, licensed influenza vaccines need yearly reformulation and come with variable vaccine efficacy. • Host immune responses to influenza virus infection or influenza vaccination can guide influenza vaccine development. View article Special Issue on: ...
The efficacy of influenza virus vaccines vary year to year, from around 10–60%12. An ideal universal Influenza vaccine would provide durable protection against circulating strains, seasonal and pre-pandemic13. Computationally optimized broadly reactive antigen (COBRA) methodology has been utilized to ...
Fluzone High-Dose: Safety and efficacy not established in pediatric patients.Because seasonal influenza vaccine inactivated is not indicated in infants <6 months of age, all household and other close contacts (e.g., day-care providers) of infants <6 months of age should be vaccinated against ...
Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine. From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, wherea...
Depending on age, immune status and circulating influenza variants, vaccine efficacy varies (Bosaeed and Kumar, 2018; Pebody et al., 2019, 2020). Guidelines are produced each year on the recommended groups who should receive the influenza vaccine (Grohskopf et al., 2020). Antiviral ...